Vol. 23/No. 6 | OncologyLive

SERDs, ESR1 Mutations Dominate Updates in ER-Positive Breast Cancer

March 31, 2022

Sara A. Hurvitz, MD, FACP, led a panel of breast cancer experts—Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky, MD, MS—in a review of key data from the 2021 San Antonio Breast Cancer Symposium in ER-positive breast cancer.

Targeted Combo Notches Rare Success in Glioblastoma

March 30, 2022

Encouraging response rates to a dual-targeted regimen in patients with recurrent or refractory malignant brain tumors with BRAF V600E mutations were reported in 2021, representing a new potential targeted therapy strategy against glioblastoma.

Precursor Conditions Unlock Potential for Early Interventions in Multiple Myeloma

March 29, 2022

Data presented at the ASH Annual Meeting and Exposition underscored the growing focus on improving screening, advancing methods of detection, and improving our understanding of the genomic, genetic, and epigenetic factors that govern progression and therapeutic resistance in multiple myeloma.

Cilta-cel Offers Durable Option for Heavily Pretreated Multiple Myeloma

March 23, 2022

OncologyLive

The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma, following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.